Content always taken with a grain of salt. Thread sponsored by Morton's....Always a safe position to take.
OT: Stock and Investment Thread
- Thread starter RU05
- Start date
Great article, who are the top fund managers buying? SCHW tops the list!
@phs73rc77gsm83 - Lots of folks also buying PFE.
:quality(80)/cloudfront-us-east-1.images.arcpublishing.com/morningstar/SJMZPQWEPJF2BGQRSFLRG6NDPM.png)
@phs73rc77gsm83 - Lots of folks also buying PFE.
Wouldn’t this be quite the wonder drug if it does even more than treat diabetes and lately weight loss.
It treats addiction? But. But. But no more hookers and blow?
Well the high can be replaced by the high you feel if you own NVO lol.It treats addiction? But. But. But no more hookers and blow?
Actually, you know what maybe not. If it's affecting dopamine for the bad stuff, I guess it probably affects dopamine for the good things too. So you'll be a very rich dull boring person lol.
Looking at AI's chart, the volume which it has sold at in 2023 dwarfs it's historical average(only became public late 2020).
And the trend in 2023 is the stock price spikes on high volume, then slips downward as volume abates. This most recent run here in late may was more modest in terms of price appreciation as well as volume relative for 2023, but still very significant relative to it's historical. Point being, we just had a volume spike, and if trend continues I expect volume to mellow, and the price to come down. So I think you may be able to tighten up the call strike price.
Currently $26.50. I'm short this weeks $23.50 puts, probably a decent bet those expire, but I may look to lower that strike going fwd.
For anyone interested in the fundamentals here, market cap of $3b, currently not profitable, and not expected to be as far out as 2025, price to rev's pretty expensive at $11x, with pretty modest rev growth around 15-20%, both in it's short history and the projected's. Unless those projections are way under (or maybe a buyout possibility) I don't see this as a good entry point as an investment.
Seems somewhat reminiscent of many fans writing off the NFL because of those kneeling during the anthem. As we know, that has completely blown over.
Not sure if the recent controversies are baked into current projections, but OK rev growth looking fwd, but excellent EPS growth. Current P/E of 16x, EPS of $3.20. EPS of $5 expected in 2026. P/E prior to Covid lows over 20x.
Throw a 20x on those 2026 earnings and you have a $100 stock.
I agree wait to see where it settles. It bounced after the initial controversy dip, but has since fell below that initial low. So I wouldn't bet this is the near term low.
Might be support in the mid $50's? 2022 lows in the mid $40's. Covid lows around $40.
Last edited:
It's lingering around the 200DMA now and it could hold there for a bit but if not that's where I'm thinking a more significant drop might come.
The TGT controversy some years back was what was on my mind and that blew over like they usually do.
I own PLTR. On a great rip this month, since it too said the magic words.
Think it might be a similar story to AI, with a high volume/stock price spike, followed by a tail off, so I sold next week's $12 calls for 4ish% premium.
If it gets called away, I'm good for a 45ish% win.(plus some premiums along the way, but not a lot).
Think it might be a similar story to AI, with a high volume/stock price spike, followed by a tail off, so I sold next week's $12 calls for 4ish% premium.
If it gets called away, I'm good for a 45ish% win.(plus some premiums along the way, but not a lot).
A potential difference between BUD and the NFL is there are alternatives to the former.
So an old timey bud drinker may switch beers rather then associate with a trans girl every time he drinks a beer.
And I don't see a ton of Devan(is that her name?) fans becoming bud lite drinkers.
We should find out in the next few hours whether that trade is going our way.
I usually don’t buy ahead of earnings but we’ll see. Maybe they’ll announce some AI developments or that they bought Neeva, because investing in cloud hyper scaling is so 2021.
We’ve held PFE for a long time. Lots of potentially great drugs being developed in the industry.Great article, who are the top fund managers buying? SCHW tops the list!
@phs73rc77gsm83 - Lots of folks also buying PFE.
One of the first stocks I ever bought 20 plus years ago through a DRIP. Honestly, I think it’s been a dog for that time period. I still own it through that but I’m quite eh about it for the most part.
Had a lot of trouble replacing Lipitor and got so big it took a ton to move the needle in terms of growth.
PFE's earnings look to be down pretty significantly yoy now that Covid vaccine's are behind us.
Still it did beat by 25% in the first quarter, and even with current projected EPS it's at about 12x 2023 earnings. And healthy beats are pretty much the norm for PFE.
Current P/E of 7x ttm. Current div of 4%.
Oops, Fat finger. My eye sight is going. I thought SCHD was the one in question. SCHD (etf) in the low 60’s is the one I’m really interested in. I’ll be watching closely at those levels and be ready to pounce.
PFE was a mid $40's stock way back in 1999. Topped out at around that level in 2000, then fell into the teens in 2008. Pressed up against that mid 40's level again in 2018 before falling off.
Broke through post Covid, but couldn't hold. Now is it still in a support level?
Current P/E is right about where it was at the lows in 2008-2009.
A wider loss then expected, and forecasted Rev growth cut from 40% to 34%.
Great thing about all that COVID cash was having the resources for M&A and increased internal R&D spending. That's how a pharma company overcomes a significant patent cliff (which happens for Pfizer in 2026-2027). I think they are well positioned to mitigate this risk.
Last edited:
BOOM!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
One of my biggest holdings (#4 behind MSFT, AAPL, and GOOGL).
What's in the DRIP I've held all along but anything outside of that I just trade. It's not a stock I think much of in the pharma space, it's average at best. Back then biotechs like Genentech, Celgene, Amgen would've been better and then a tried and true name like JNJ as well which I have also held for long time.
PFE IMO has mostly been mismanaged and became too big with acquisitions to obtain drugs. Spent a lot on R&D during those 20 plus years but not sure they ever came out with ton on their own and certainly not much to move the needle for a company that size.
Same, and we had a golden opportunity not too long ago.